Can we actually slow the progression of type 1 diabetes after diagnosis?

This episode of the PeerDirect Medical News Podcast highlights three major developments shaping diabetes and hematologic oncology care. First, the FDA expanded approval of teplizumab for selected children and adolescents with newly diagnosed Stage 3 type 1 diabetes, making it the first therapy to modify disease progression after diagnosis by preserving beta-cell function. Additional stories review evidence supporting continuous glucose monitoring in basal insulin-treated type 2 diabetes and promising Phase III data showing talquetamab-based bispecific antibody regimens improve outcomes in relapsed or refractory multiple myeloma.